ABSTRACT
In this study, the authors report their experience with latanoprost after a year's treatment of patients with various forms of glaucoma at various stages of progression. The new drug was associated also with different beta-blockers. The case file reported includes 30 eyes of 18 patients treated with latanoprost once a day in the evening. Follow-up varied from 6 months to 1 year. Except for 2 patients (3 eyes) receiving only latanoprost therapy, all the others received latanoprost in association with their on-going therapy. Results are equivalent to those described in the literature. The authors also consider the results in two groups; chronic simple glaucoma and other forms of glaucoma. From their own experience and from what is reported in the literature, the authors conclude by stressing the pressure reducing efficacy of this drug.
Subject(s)
Glaucoma, Open-Angle/drug therapy , Intraocular Pressure/drug effects , Prostaglandins F, Synthetic/therapeutic use , Sympathetic Nervous System/drug effects , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/therapeutic use , Adult , Aged , Chronic Disease , Drug Therapy, Combination , Female , Follow-Up Studies , Glaucoma, Open-Angle/physiopathology , Humans , Latanoprost , Male , Middle Aged , Ocular Hypertension/drug therapy , Ocular Hypertension/physiopathology , Ophthalmic Solutions , Parasympathomimetics/administration & dosage , Parasympathomimetics/therapeutic use , Prostaglandins F, Synthetic/administration & dosage , Treatment Outcome , Visual Acuity/drug effectsSubject(s)
Migraine Disorders/prevention & control , Verapamil/therapeutic use , Adolescent , Adult , Female , Humans , Male , Middle Aged , Verapamil/adverse effectsSubject(s)
Calcium Channel Blockers/therapeutic use , Cinnarizine/therapeutic use , Migraine Disorders/drug therapy , Piperazines/therapeutic use , Adult , Blood Pressure/drug effects , Cinnarizine/analogs & derivatives , Cinnarizine/pharmacology , Clinical Trials as Topic , Female , Flunarizine , Heart Rate/drug effects , Humans , Male , Middle Aged , Migraine Disorders/physiopathology , Migraine Disorders/prevention & controlABSTRACT
The Authors, starting with the hypothesis that could exist a correlation between the opiate withdrawal and the migraine crisis, used the naloxone, opiate pure antagonist, in order to induced the migraine crisis. 30 patients affected by migraine were studied; naloxone was administered acutely (2 mg e.v.) during the asintomatic period. The naloxone administration never caused the migraine crisis. The patients didn't complain variations regarding the psycho-physical status or the monitored clinical parameters.
Subject(s)
Migraine Disorders/chemically induced , Naloxone , Substance Withdrawal Syndrome , Adolescent , Adult , Female , Humans , Male , Middle Aged , Migraine Disorders/etiology , NarcoticsABSTRACT
The authors evaluated the efficacy of a DHE methanesulphonate for migraine attacks and its tolerability on liver, gallbladder and cardiovascular system functions. Twenty-eight patients affected by migraine were studied. They were withdrawn from preventive therapy for at least one month and treated for three months. The drug showed a good efficacy with a statistical significant reduction of severity and duration of attacks. No variation of the biochemical and morphological parameters of liver, gallbladder and cardiovascular function were found throughout the treatment.
Subject(s)
Dihydroergotamine/analogs & derivatives , Migraine Disorders/prevention & control , Adolescent , Adult , Delayed-Action Preparations , Dihydroergotamine/pharmacology , Dihydroergotamine/therapeutic use , Drug Tolerance , Female , Humans , Male , Middle Aged , Migraine Disorders/drug therapySubject(s)
Clonidine/therapeutic use , Migraine Disorders/drug therapy , Adolescent , Adult , Clinical Trials as Topic , Drug Evaluation , Female , Humans , Male , Middle AgedABSTRACT
Two cases of non-familial hemiplegic migraine are described. Naloxone reversed the neurological deficits accompanying attacks, whereas the pain was uninfluenced. The possibility that the opiate-antagonist naloxone facilitates regression of neurological symptoms associated with migraine attacks in general is voiced.
